Britain defends investment record as Merck scraps labs over pharma environment

U.S. drugmaker Merck has abandoned its new London research center, citing the UK's lack of investment in life sciences and undervaluation of innovative medicines, further escalating concerns for Britain's pharmaceutical sector. This decision, following AstraZeneca's scrapped UK vaccine plant, highlights a challenging business environment that has seen the UK's pharmaceutical FDI ranking fall from second to seventh globally since 2017, compounded by ongoing NHS revenue disputes and potential U.S. tariff pressures. While the UK government defends its investment appeal, it acknowledges the need for further work to attract and retain pharmaceutical sector capital.

Analysis

Merck's (MRK) decision to abandon its new London research center, despite construction already being underway for a 2027 opening, signals a significant escalation of concerns regarding the UK's life sciences investment climate. This move is not an isolated event, following AstraZeneca's (AZN) recent cancellation of a £450 million vaccine plant. According to the Association of the British Pharmaceutical Industry, these actions reflect a deteriorating environment that has seen the UK's global ranking for pharmaceutical FDI fall from second in 2017 to seventh in 2023. Key drivers cited by Merck include the UK's perceived undervaluation of innovative medicines and a lack of progress in addressing investment shortfalls, directly referencing the stalled negotiations with the National Health Service over revenue clawbacks. Compounding these domestic issues is external pressure from the U.S. administration, which is pushing for increased spending on American-made drugs and considering pharmaceutical tariffs, adding a layer of geopolitical risk to UK-based operations. While the UK government cited a £520 million manufacturing fund and a favorable Deloitte survey, its acknowledgment that the news is 'concerning' highlights a potential disconnect with industry sentiment.

Key Decisions for Investors

• Investors should re-evaluate the risk profile of pharmaceutical companies with significant UK operational exposure, such as GSK, as the withdrawals by Merck and AstraZeneca indicate a worsening business and regulatory environment.
• The outcome of stalled pricing negotiations between drug companies and the UK's National Health Service is a critical catalyst to monitor; an unfavorable resolution could further damage sector sentiment and trigger more divestment.
• Consider the growing geopolitical risk from potential U.S. pharmaceutical tariffs, which could materially impact the profitability of companies manufacturing in or exporting from the UK, warranting close attention to upcoming UK-U.S. trade discussions.